The Lancet December 22, 2022

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher C Butler et al.

Bottom Line

In a highly vaccinated community population of high-risk adults with early COVID-19, adding molnupiravir to usual care did not reduce the frequency of hospitalizations or deaths but was associated with a faster self-reported recovery time.

Key Findings

1. Molnupiravir did not reduce the incidence of COVID-19-associated hospitalizations or death within 28 days compared to usual care alone (105 [1%] of 12,529 participants vs 98 [1%] of 12,525; adjusted odds ratio 1.06, 95% Bayesian credible interval 0.81-1.41).

2. The absolute risk of the primary outcome was extremely low (~1%) in both groups, primarily reflecting the strong protective effect of existing immunity (94% had received at least 3 vaccine doses) and the Omicron variant.

3. Participants receiving molnupiravir experienced a significantly faster time to first self-reported recovery (median 9 days vs 15 days).

4. No serious adverse events related to molnupiravir were reported (severe adverse events occurred in 0.4% of the molnupiravir group vs 0.3% of the usual care group).

Study Design

Design

Open-Label RCT

Open-Label

Sample

25,708

Patients

Duration

28 days

Median

Setting

UK community

Population Adults aged >=50 years, or >=18 years with relevant comorbidities, unwell with confirmed COVID-19 for <=5 days in the community (94% had received >=3 vaccine doses).

Intervention Molnupiravir 800 mg orally twice daily for 5 days plus usual care.

Comparator Usual care alone.

Outcome All-cause hospitalisation or death within 28 days of randomisation.

Study Limitations

• The open-label design introduces a significant risk of performance and reporting bias, particularly for self-reported secondary outcomes such as recovery time and symptom alleviation.

• The population's very low baseline incidence of hospitalization or death (~1%) severely limited the statistical power to detect any small relative differences in the primary outcome.

• Conducted predominantly during the Omicron wave in a highly vaccinated UK population, the findings may not be generalizable to completely unvaccinated populations or novel, more virulent variants.

• Secondary clinical endpoints relied heavily on participants completing a daily online diary, which may be subject to incomplete data or differential attrition.

Clinical Significance

The PANORAMIC trial provides compelling evidence that the routine use of molnupiravir to prevent hospitalization or death is not justified in a highly vaccinated, high-risk community population infected with contemporary COVID-19 variants, as baseline immunity already keeps severe outcomes exceedingly rare (~1%). However, its ability to accelerate recovery time by roughly 4 days suggests it may still have a role in specific clinical scenarios, such as treating debilitating symptoms or mitigating outbreaks in high-risk congregate settings, though cost-effectiveness remains a consideration.

Historical Context

Molnupiravir, an oral nucleoside analogue that induces lethal viral mutagenesis, was initially authorized based on the phase 3 MOVe-OUT trial, which demonstrated a ~30% relative risk reduction in hospitalization or death among high-risk, unvaccinated patients prior to the Omicron variant. To evaluate the drug's real-world utility during the Omicron surge, the UK launched PANORAMIC, a massive, pragmatic platform trial. By showing no measurable benefit in preventing severe disease among highly vaccinated individuals, PANORAMIC challenged the routine prescription of molnupiravir for preventing hospital admission in populations with robust pre-existing immunity, while simultaneously highlighting its potential utility in accelerating symptom resolution.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the mechanism of action of molnupiravir, and how was this mechanism theoretically expected to reduce the risk of severe COVID-19?

Key Response

Molnupiravir is an oral ribonucleoside prodrug that is incorporated into viral RNA, inducing viral lethal mutagenesis. Understanding this helps students connect foundational virology to the clinical rationale for early antiviral administration before the inflammatory phase of COVID-19 begins.

Resident

Given that the PANORAMIC trial showed no mortality or hospitalization benefit but demonstrated a faster self-reported recovery, how should you counsel a high-risk, vaccinated outpatient requesting a molnupiravir prescription?

Key Response

Residents must practice evidence-based shared decision-making, explaining that while the medication might make them feel better a few days sooner, it does not prevent hospitalization or death in vaccinated individuals, making its routine use difficult to justify given potential toxicities and alternative therapies.

Fellow

The PANORAMIC trial contrasts starkly with the earlier MOVe-OUT trial, which showed a significant reduction in hospitalization or death. What key differences in the trial populations and circulating variants account for these discrepant findings?

Key Response

Fellows must critically appraise shifting clinical contexts. MOVe-OUT evaluated unvaccinated patients during the Delta wave, whereas PANORAMIC evaluated a highly vaccinated cohort during the Omicron wave, demonstrating how baseline host immunity and viral variant evolution can nullify previously established antiviral efficacy.

Attending

How do you use the PANORAMIC trial results to teach your medical team about the inherent limitations of subjective secondary endpoints in open-label randomized controlled trials?

Key Response

Attendings must foster critical appraisal skills. Because PANORAMIC was open-label, the faster self-reported recovery time is highly susceptible to the placebo effect. This teaches learners to interpret subjective secondary benefits with profound skepticism when the objective primary endpoints are negative.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The PANORAMIC trial utilized a large-scale, open-label, platform-adaptive design. What are the statistical and epidemiological trade-offs of using this pragmatic design for evaluating both objective and subjective endpoints during an infectious disease pandemic?

Key Response

Researchers must weigh trial feasibility against bias. While an open-label adaptive platform allows rapid recruitment and real-world applicability during a crisis, it introduces severe ascertainment bias and placebo effects for subjective endpoints, though hard objective endpoints like mortality remain methodologically robust.

Journal Editor

As a peer reviewer or editor evaluating the PANORAMIC manuscript, how would you address the authors' emphasis on the secondary outcome of faster recovery time, and what strict reporting guardrails would you mandate?

Key Response

Editors must guard against outcome reporting bias or spin. Emphasizing a subjective secondary outcome in an open-label trial when the primary objective outcome failed is a major methodological red flag, requiring strict editorial mandates to ensure the abstract predominantly reflects the lack of objective clinical benefit.

Guideline Committee

How should the PANORAMIC trial findings influence IDSA and NIH COVID-19 treatment guidelines regarding the tier-based prioritization of molnupiravir, specifically for vaccinated populations?

Key Response

Guidelines initially listed molnupiravir as an alternative outpatient therapy. PANORAMIC provides definitive evidence that it lacks objective benefit in vaccinated individuals, prompting guideline committees to strongly recommend against its routine use in this demographic and deprioritize it further behind ritonavir-boosted nirmatrelvir and remdesivir.

Clinical Landscape

Noteworthy Related Trials

2021

MOVe-OUT Trial

n = 1,433 · NEJM

Tested

Molnupiravir 800mg twice daily for 5 days

Population

Unvaccinated, non-hospitalized adults with mild-to-moderate COVID-19 and at least one risk factor

Comparator

Placebo

Endpoint

Hospitalization or death through day 29

Key result: Molnupiravir reduced the risk of hospitalization or death from 9.7% to 6.8% compared to placebo.

2021

PINETREE Trial

n = 562 · NEJM

Tested

Intravenous Remdesivir for 3 days

Population

Non-hospitalized patients with COVID-19 at high risk for disease progression

Comparator

Placebo

Endpoint

COVID-19 related hospitalization or death from any cause by day 28

Key result: A 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo.

2022

EPIC-HR Trial

n = 2,246 · NEJM

Tested

Nirmatrelvir/ritonavir (Paxlovid) twice daily for 5 days

Population

Unvaccinated, non-hospitalized adults with mild-to-moderate COVID-19 at high risk for progression

Comparator

Placebo

Endpoint

COVID-19 related hospitalization or death from any cause through day 28

Key result: Paxlovid reduced the risk of COVID-19-related hospitalization or death by 89% compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis